Investing in AbbVie Inc. (ABBV)

Valuation methodValue, $Upside, %
Artificial intelligence (AI)41.83-74
Intrinsic value (DCF)52.86-67
Graham-Dodd Method15.31-91
Graham Formula29.60-82

Company description

AbbVie Inc. (ticker symbol ABBV) is a global pharmaceutical company that specializes in the development and manufacturing of drugs for various medical conditions. Founded in 2013 as a spin-off of Abbott Laboratories, AbbVie has grown to become a leader in the healthcare industry, generating over $45 billion in revenue in 2020. The company's main focus is researching and developing treatments for immunology, oncology, and neuroscience, but it also has a presence in other therapeutic areas. AbbVie is known for its top-selling drug Humira, which is used to treat rheumatoid arthritis and other autoimmune diseases. However, the company has an impressive portfolio of over 60 medicines, including cancer drugs Imbruvica and Venclexta, testosterone replacement therapy AndroGel, and HIV treatment Kaletra. The company also has a strong pipeline of new drugs in various stages of development. AbbVie's commitment to innovation and patient care has earned it a reputation as a trusted and reliable healthcare partner. With a global presence in over 175 countries and a workforce of over 47,000 employees, AbbVie is dedicated to making a lasting impact on the lives of patients worldwide.